Braveheart Bio closed a $185 million financing led by top life‑science investors to fund registration‑enabling studies of a small‑molecule candidate licensed from Jiangsu Hengrui for hypertrophic cardiomyopathy (HCM). The new company named an experienced leadership team and attracted a high‑profile board chair to oversee clinical development and global commercialization planning. The funding will support global late‑stage trials and regulatory strategy for an indication with substantial unmet need and established commercial opportunity.